These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15597098)

  • 21. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments.
    Buccheri G; Torchio P; Ferrigno D
    Chest; 2003 Aug; 124(2):622-32. PubMed ID: 12907552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Ishikawa N; Hattori N; Yokoyama A; Tanaka S; Nishino R; Yoshioka K; Ohshimo S; Fujitaka K; Ohnishi H; Hamada H; Arihiro K; Kohno N
    Int J Cancer; 2008 Jun; 122(11):2612-20. PubMed ID: 18324627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
    Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer.
    Niklinski J; Burzykowski T; Niklinska W; Laudanski J; Chyczewski L; Rapellino M; Furman M
    Eur Respir J; 1998 Dec; 12(6):1424-8. PubMed ID: 9877503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
    Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
    Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
    Giaccone G; Iacona RB; Fandi A; Janas M; Ochs JS; Herbst RS; Johnson DH
    J Cancer Res Clin Oncol; 2009 Mar; 135(3):467-76. PubMed ID: 18787840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early CYFRA 21-1 variation predicts tumor response to chemotherapy and survival in locally advanced non-small cell lung cancer patients.
    Merle P; Janicot H; Filaire M; Roux D; Bailly C; Vincent C; Gachon F; Tchirkov A; Kwiatkowski F; Naamé A; Escande G; Caillaud D; Verrelle P
    Int J Biol Markers; 2004; 19(4):310-5. PubMed ID: 15646838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.
    Barlési F; Gimenez C; Torre JP; Doddoli C; Mancini J; Greillier L; Roux F; Kleisbauer JP
    Respir Med; 2004 Apr; 98(4):357-62. PubMed ID: 15080079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib.
    Azuma K; Komatsu N; Hattori S; Matsueda S; Kawahara A; Sasada T; Itoh K; Hoshino T
    PLoS One; 2014; 9(1):e86667. PubMed ID: 24497964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.
    Wu JY; Shih JY; Yang CH; Chen KY; Ho CC; Yu CJ; Yang PC
    Int J Cancer; 2010 Jan; 126(1):247-55. PubMed ID: 19536777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
    Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
    J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gefitinib for advanced non-small cell lung cancer.
    Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304.
    Edelman MJ; Hodgson L; Rosenblatt PY; Christenson RH; Vokes EE; Wang X; Kratzke R
    J Thorac Oncol; 2012 Apr; 7(4):649-54. PubMed ID: 22425913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.
    Suzuki H; Ishikawa S; Satoh H; Ishikawa H; Sakai M; Yamamoto T; Onizuka M; Sakakibara Y
    Eur J Cardiothorac Surg; 2007 Oct; 32(4):648-52. PubMed ID: 17707649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study.
    Ono A; Takahashi T; Mori K; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Nakajima T; Endo M; Yamamoto N
    BMC Cancer; 2013 Jul; 13():354. PubMed ID: 23879483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients.
    Bréchot JM; Chevret S; Nataf J; Le Gall C; Frétault J; Rochemaure J; Chastang C
    Eur J Cancer; 1997 Mar; 33(3):385-91. PubMed ID: 9155521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.
    Okami J; Taniguchi K; Higashiyama M; Maeda J; Oda K; Orita N; Koizumi K; Kodama K; Kato K
    Oncology; 2007; 72(3-4):234-42. PubMed ID: 18176089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.